<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medical management of the dialysis patient undergoing surgery</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medical management of the dialysis patient undergoing surgery</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Medical management of the dialysis patient undergoing surgery</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Neil S Sanghani, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ramesh Soundararajan, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael F O'Connor, MD, FCCM</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Nussmeier, MD, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1829252588"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with end-stage kidney disease (ESKD) who are on dialysis commonly require surgery or other invasive procedures for reasons related to ESKD, including vascular access procedures, parathyroidectomy, or kidney transplantation. Patients may also require elective or emergency procedures for reasons unrelated to their ESKD.</p><p>This topic reviews the preoperative and postoperative medical management of patients on dialysis. Anesthetic management of patients on dialysis and issues specific to patients on peritoneal dialysis undergoing surgery are discussed separately. (See  <a class="medical medical_review" href="/d/html/94254.html" rel="external">"Anesthesia for dialysis patients"</a> and  <a class="medical medical_review" href="/d/html/139769.html" rel="external">"Issues in patients on peritoneal dialysis undergoing surgery"</a>.)</p><p class="headingAnchor" id="H1299491651"><span class="h1">OUTCOMES AFTER SURGERY</span><span class="headingEndMark"> — </span>Patients on dialysis have a higher perioperative mortality compared with patients without end-stage kidney disease (ESKD) [<a href="#rid1">1-3</a>]. For example, in a study of 1157 patients with ESKD who had repair of abdominal aortic aneurysm, perioperative mortality was 16 percent for open surgical repair and 10 percent for endovascular repair [<a href="#rid3">3</a>]. By contrast, patients without ESKD had lower perioperative mortality after either open surgery (1 to 5 percent) or endovascular repair (approximately 1 percent) [<a href="#rid4">4-6</a>].</p><p>Possible causes of increased morbidity and mortality among patients on dialysis include higher likelihood of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular complications (see <a class="local">'Cardiovascular disease'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perioperative fluid and electrolytes disturbances, particularly hyperkalemia [<a href="#rid7">7</a>] (see <a class="local">'Indications for urgent preoperative dialysis'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical bleeding complications (see <a class="local">'Bleeding diathesis'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poor perioperative blood pressure control (both hypertension and hypotension) (see <a class="local">'Hypertension'</a> below)</p><p></p><p>Also, patients on dialysis require increased medical support during the perioperative period, including increased need for vasopressors or antihypertensive agents, and increased duration of mechanical ventilation, intensive care, and inpatient hospitalization [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H2793164996"><span class="h1">PREOPERATIVE EVALUATION</span><span class="headingEndMark"> — </span>For most planned surgical procedures, preoperative medical evaluation of patients on dialysis includes baseline laboratory testing, determining the adequacy of hemodialysis or peritoneal dialysis access, and assessing comorbidities. Preoperative considerations for patients on peritoneal dialysis, including which patients may need to switch to temporary hemodialysis due to surgery, are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/139769.html" rel="external">"Issues in patients on peritoneal dialysis undergoing surgery", section on 'Preoperative considerations'</a>.)</p><p class="headingAnchor" id="H3373705418"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>The following laboratory tests are obtained after the most recent preoperative dialysis treatment: </p><p class="bulletIndent1"><span class="glyph">●</span>Serum electrolytes, glucose, blood urea nitrogen, creatinine, calcium, magnesium, phosphorus, and albumin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coagulation tests, including prothrombin time, activated partial thromboplastin time, and international normalized ratio. However, a bleeding time is not recommended as a preoperative screening test. Although some studies have found a good correlation between uremic bleeding and the bleeding time [<a href="#rid9">9,10</a>], a normal bleeding time does not predict the safety of surgical procedures, nor does a prolonged bleeding time predict excessive bleeding. Assessment of the bleeding time is subject to considerable variation due to technical factors in executing the test. (See  <a class="medical medical_review" href="/d/html/3067.html" rel="external">"The kidney biopsy", section on 'Patient evaluation'</a>.)</p><p></p><p>Results of these tests guide the dialysis prescription and provide preoperative baseline values. The time interval between the last dialysis treatment and preoperative laboratory testing should also be considered when interpreting the results. Additional laboratory testing should be tailored to the requirements of the individual patient. In particular, drug concentrations of <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> or other medications with a narrow therapeutic index should be checked.</p><p class="headingAnchor" id="H491687674"><span class="h2">Assessment of access</span><span class="headingEndMark"> — </span>The access site for hemodialysis or peritoneal dialysis should be examined to exclude evidence of infection. (See  <a class="medical medical_review" href="/d/html/89537.html" rel="external">"Physical examination of the arteriovenous graft", section on 'Infected graft'</a> and  <a class="medical medical_review" href="/d/html/1924.html" rel="external">"Physical examination of the mature hemodialysis arteriovenous fistula", section on 'Infection'</a>.)</p><p>The fistula or graft should be assessed for patency by clinical examination. The access site should be clearly marked and staff warned about its location. (See  <a class="medical medical_review" href="/d/html/89537.html" rel="external">"Physical examination of the arteriovenous graft", section on 'Thrombosed graft'</a> and  <a class="medical medical_review" href="/d/html/1924.html" rel="external">"Physical examination of the mature hemodialysis arteriovenous fistula", section on 'Thrombosed AV fistula'</a>.)</p><p class="headingAnchor" id="H3114472286"><span class="h2">Assessment of comorbidities</span><span class="headingEndMark"> — </span>Patients on dialysis commonly have multisystem comorbidities that may impact anesthetic and surgical care.</p><p class="headingAnchor" id="H4045536589"><span class="h3">Cardiovascular disease</span><span class="headingEndMark"> — </span>Coronary artery disease and myocardial dysfunction are the most common morbidities in patients with end-stage kidney disease (ESKD), causing significant morbidity and mortality even among those not undergoing surgery [<a href="#rid11">11</a>]. In some series, approximately 50 percent of patients on dialysis undergoing surgery have cardiovascular disease [<a href="#rid7">7,12</a>]. (See  <a class="medical medical_review" href="/d/html/1846.html" rel="external">"Overview of screening and diagnosis of heart disease in patients on dialysis"</a> and  <a class="medical medical_review" href="/d/html/1892.html" rel="external">"Clinical manifestations and diagnosis of coronary artery disease in end-stage kidney disease (dialysis)"</a>.)</p><p>Preoperative evaluation and management of cardiac risk for patients on dialysis is similar to those for other patients undergoing noncardiac surgery, as discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/6616.html" rel="external">"Evaluation of cardiac risk prior to noncardiac surgery"</a> and  <a class="medical medical_review" href="/d/html/6615.html" rel="external">"Management of cardiac risk for noncardiac surgery"</a>.)</p><p>Aortic stenosis is common and often severe in patients with ESKD. Patients with limited exercise tolerance and a characteristic systolic ejection murmur should be evaluated for the severity of their aortic stenosis prior to undergoing any other anesthetic or surgery [<a href="#rid13">13,14</a>]. (See  <a class="medical medical_review" href="/d/html/1909.html" rel="external">"Valvular heart disease in patients with end-stage kidney disease", section on 'Aortic stenosis'</a>.) </p><p class="headingAnchor" id="H1836494404"><span class="h3">Hypertension</span><span class="headingEndMark"> — </span>Hypertension is common among patients on dialysis. Management of chronically administered oral antihypertensive agents is discussed below. (See  <a class="medical medical_review" href="/d/html/1848.html" rel="external">"Hypertension in patients on dialysis"</a> and <a class="local">'Medication management'</a> below.)</p><p>If blood pressure (BP) is significantly elevated before surgery, initial management includes dialysis to remove fluid and optimize volume status since volume overload is likely to be the cause (see  <a class="medical medical_review" href="/d/html/94254.html" rel="external">"Anesthesia for dialysis patients", section on 'Management of intravascular volume overload'</a>). However, antihypertensive therapy may be necessary if BP remains significantly elevated after attaining optimal dry weight, or if dialysis cannot be performed in the immediate preoperative period (eg, need for emergency surgery). Typically, intravenous (IV) antihypertensive therapy is used, with selection of an agent such as <a class="drug drug_general" data-topicid="17094" href="/d/drug information/17094.html" rel="external">enalaprilat</a>, <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a>, <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a> (administered with a beta blocker to minimize the effect of reflex sympathetic activation), <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>, and/or <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a>. The choice of agent may be influenced by the patient's baseline vital signs (eg, hydralazine if bradycardia is present, or a beta blocker if tachycardia is present) as well as interactions with other drugs they are receiving. If the patient is monitored in an intensive care unit, IV <a class="drug drug_general" data-topicid="9697" href="/d/drug information/9697.html" rel="external">nicardipine</a> may be selected.</p><p><a class="drug drug_general" data-topicid="8911" href="/d/drug information/8911.html" rel="external">Clevidipine</a> is selected to treat malignant hypertension in some centers. Notably, transdermal rather than IV administration of clevidipine results in slower attainment of adequate blood levels and may not achieve immediate control of BP. However, this route is useful when BP control is less urgent or in the postoperative period.</p><p>During the intraoperative period, only short-acting agents are used to control BP due to the potential for rapid blood loss or other fluid shifts and development of hypotension  (<a class="graphic graphic_table graphicRef119750" href="/d/graphic/119750.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H101079446"><span class="h3">Diabetes</span><span class="headingEndMark"> — </span>Many patients on dialysis have diabetes. In those without diabetes, glucose intolerance is a feature of uremia that may result in hyperglycemia, particularly in the perioperative period. Administration of glucose-containing solutions such as parenteral hyperalimentation will exacerbate hyperglycemia in these patients. General considerations in the perioperative care of patients with diabetes are discussed separately. (See  <a class="medical medical_review" href="/d/html/1753.html" rel="external">"Perioperative management of blood glucose in adults with diabetes mellitus"</a>.)</p><p>Specific considerations for perioperative care of patients on dialysis who have diabetes include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>All patients with diabetes</strong> – Issues specific to patients on dialysis who have diabetes include:  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IV fluids should contain dextrose if the patient is fasting; insulin coverage is adjusted accordingly. A potential advantage of dextrose-containing solutions is reducing the likelihood of hyperkalemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Insulin requirements of patients on peritoneal dialysis may change depending on whether or not exchanges are being performed. Unless contraindicated, patients on peritoneal dialysis should continue exchanges while awaiting surgery; however, their peritoneum should be drained prior to any surgical or endoscopic procedure. In such circumstances, insulin requirements often change since glucose is absorbed from peritoneal fluid during exchanges (and this source of glucose is eliminated when exchanges are stopped).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with years of experience in determining the particular dose of insulin required for their glucose control in different settings should be consulted to help determine the dose of insulin that will be necessary during hospitalization.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among patients in whom diabetic ketoacidosis is suspected, serum ketones must be measured. Notably, urine ketones are not useful. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 1 diabetes </strong>– Patients on dialysis who have type 1 diabetes may be more brittle than other patients with type 1 diabetes. Given the effects of surgical stress on glucose metabolism, perioperative management may be challenging.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 2 diabetes </strong>– Among patients on dialysis who have type 2 diabetes, the potential for hyperglycemia with surgery is often underestimated. This is because oral hypoglycemic agents are often discontinued in such patients when they start dialysis because insulin requirements decrease with ESKD. Conversely, patients on dialysis who have type 2 diabetes who continue oral hypoglycemic agents may develop profound hypoglycemia if they cannot eat during the perioperative period since the half-life of some oral hypoglycemics is increased in patients with kidney failure. In some cases, administration of <a class="drug drug_general" data-topicid="8711" href="/d/drug information/8711.html" rel="external">IV dextrose</a> for approximately 48 hours may be necessary to maintain blood glucose.</p><p></p><p class="headingAnchor" id="H2242508987"><span class="h3">Anemia</span><span class="headingEndMark"> — </span>Ideally, the preoperative hemoglobin concentration should be at the recommended target for patients with ESKD. (See  <a class="medical medical_review" href="/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis", section on 'Target Hb levels'</a>.)</p><p>If a patient on dialysis has a hemoglobin less than the target before planned surgery, an evaluation for causes of blood loss or erythropoiesis-stimulating agent (ESA) resistance should be undertaken. ESAs are typically adjusted preoperatively to bring the baseline hemoglobin closer to goal, if feasible. Iron studies should also be performed since iron deficiency can contribute to anemia and ESA resistance. (See  <a class="medical medical_review" href="/d/html/1953.html" rel="external">"Treatment of iron deficiency in patients on dialysis"</a> and  <a class="medical medical_review" href="/d/html/94347.html" rel="external">"Perioperative blood management: Strategies to minimize transfusions", section on 'Treatment of anemia'</a>.)</p><p class="headingAnchor" id="H3731329627"><span class="h3">Bleeding diathesis</span><span class="headingEndMark"> — </span>Patients with ESKD may have an increased tendency to bleed during and/or after surgery due to multiple factors such as retention of uremic toxins due in part to inadequate dialysis, anemia, excess parathyroid hormone, residual heparin used during recent hemodialysis, or chronic administration of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> [<a href="#rid15">15,16</a>]. However, not all uremic patients have a bleeding diathesis, and some are actually hypercoagulable [<a href="#rid15">15,17-19</a>]. </p><p>Preoperative measures to minimize uremic bleeding during and after surgery are discussed elsewhere. (See <a class="local">'Uremic bleeding'</a> below and  <a class="medical medical_review" href="/d/html/94254.html" rel="external">"Anesthesia for dialysis patients", section on 'Management of bleeding'</a>.) </p><p>Causes and treatment of platelet dysfunction in patients with ESKD are discussed in a separate topic. (See  <a class="medical medical_review" href="/d/html/1947.html" rel="external">"Uremic platelet dysfunction"</a>.)</p><p class="headingAnchor" id="H1680701009"><span class="h3">Nutritional status</span><span class="headingEndMark"> — </span>It is important to identify patients at high risk for protein-energy wasting in the preoperative period [<a href="#rid20">20</a>]. Assessment and management of nutritional status in dialysis patients are discussed in other topics:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1850.html" rel="external">"Assessment of nutritional status in patients on hemodialysis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1856.html" rel="external">"Pathogenesis and treatment of malnutrition in patients on maintenance hemodialysis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1855.html" rel="external">"Nutritional status and protein intake in patients on peritoneal dialysis"</a>.)</p><p></p><p class="headingAnchor" id="H3384351293"><span class="h1">PREOPERATIVE MANAGEMENT</span></p><p class="headingAnchor" id="H3761704538"><span class="h2">Dialysis considerations</span></p><p class="headingAnchor" id="H2544316599"><span class="h3">Routine dialysis prior to surgery</span><span class="headingEndMark"> — </span>Our approach to preoperative dialysis differs depending on whether the patient is on hemodialysis or peritoneal dialysis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodialysis </strong>– For those patients undergoing elective surgery who are on maintenance hemodialysis, a hemodialysis treatment is usually performed when practical, either the day before or on the day of the procedure. This practice is supported by observational data suggesting that longer intervals between dialysis and surgery may increase the risk of postsurgical complications. In a retrospective cohort study of approximately 350,000 patients with end-stage kidney disease (ESKD) on hemodialysis who underwent surgery, day-long intervals between dialysis and surgery of zero (ie, dialysis on the same day of surgery), one, two, and three days were associated with 90-day postoperative mortality risks of 4, 4.2, 4.7, and 5.2 percent, respectively [<a href="#rid21">21</a>]. However, for well-dialyzed patients, we generally do not add hemodialysis treatments prior to surgery, since intensification of hemodialysis has not been shown to improve outcomes, and changes to the routine dialysis regimen can adversely impact continuity of care.</p><p></p><p class="bulletIndent1">If dialysis is provided the day of surgery, it is important to institute measures that avoid prolonged anticoagulation. (See  <a class="medical medical_review" href="/d/html/1840.html" rel="external">"Anticoagulation for the hemodialysis procedure"</a>.)</p><p></p><p class="bulletIndent1">The dialysis prescription is generally the same (or as close as possible to) the usual prescription for the individual patient. However, the patient's laboratory values (ie, serum potassium, calcium, and phosphorus) and the dialysate calcium and potassium concentration should be carefully reviewed and adjusted in order to use the dialysate potassium, calcium, and bicarbonate prescription to ensure that the patient goes to the operating room with normal or near-normal plasma concentrations.</p><p></p><p class="bulletIndent1">The amount of ultrafiltration should be carefully adjusted to ensure that the patient is at or close to dry weight prior to surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peritoneal dialysis </strong>– Some UpToDate contributors increase the amount of peritoneal dialysis before surgery to prevent underdialysis postoperatively in the event that resumption of peritoneal dialysis is delayed. Preoperative intensification of peritoneal dialysis is used even when postoperative delays in peritoneal dialysis are not expected, since unanticipated delays (eg, due to an ileus or constipation) are relatively common. However, other UpToDate contributors do not increase the amount of peritoneal dialysis in well-dialyzed patients before surgery. Preoperative intensification of peritoneal dialysis is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/139769.html" rel="external">"Issues in patients on peritoneal dialysis undergoing surgery", section on 'Intensification of peritoneal dialysis before surgery'</a>.)</p><p></p><p class="bulletIndent1">Similar to patients on hemodialysis, those on peritoneal dialysis should be at their dry weight prior to surgery. Patients should go to surgery after draining the peritoneal dialysate from the abdomen. Volume administration (in combination with vasopressors) is typically necessary during the intraoperative period to treat vasodilation and negative inotropy caused by induction and maintenance anesthetic agents and/or surgical bleeding. (See  <a class="medical medical_review" href="/d/html/94254.html" rel="external">"Anesthesia for dialysis patients", section on 'Fluid management'</a>.)</p><p></p><p class="headingAnchor" id="H3396909679"><span class="h3">Indications for urgent preoperative dialysis</span><span class="headingEndMark"> — </span>The major indications for urgent preoperative dialysis are hyperkalemia and volume overload.</p><p class="headingAnchor" id="H1280832236"><span class="h4">Hyperkalemia</span><span class="headingEndMark"> — </span>Hyperkalemia is a potential indication for urgent preoperative dialysis. There are no guidelines that specify a maximum safe level of potassium prior to induction of anesthesia. Decisions regarding treatment of hyperkalemia depend in part on the urgency of surgery (ie, whether it is safe to delay surgery for three to four hours to perform dialysis). Other factors include the likely degree of tissue damage that may cause release of potassium during the planned operation, anticipated blood loss and fluid shifts, chronicity of hyperkalemia, and existing or impending acid-base disturbances (eg, metabolic acidosis) that may affect the intraoperative rate of rise of the serum potassium concentration. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elective surgery </strong>– The serum potassium concentration should be checked on the morning of surgery; if elevated, a 12-lead electrocardiogram (ECG) is obtained; however, hyperkalemic ECG changes are often not evident  (<a class="graphic graphic_figure graphicRef109443" href="/d/graphic/109443.html" rel="external">figure 1</a>). These are due to alterations in the transcellular potassium gradient rather than the absolute serum potassium value. However, there is neither an orderly progression of ECG abnormalities in hyperkalemic patients as their potassium rises, nor does the absence of ECG changes preclude the possibility of hyperkalemia-associated cardiac arrest [<a href="#rid22">22-25</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If serum potassium concentration is &lt;5.5 mEq/L and there are no changes on the ECG, urgent dialysis is generally not necessary prior to surgery, particularly in a patient with chronic hyperkalemia. Patients on dialysis often have chronic elevations in both total body and intracellular potassium, but transcellular gradients may not be altered with moderate hyperkalemia, accounting for the absence of hyperkalemia-induced ECG changes until potassium is &gt;6 to 6.5 mEq/L [<a href="#rid22">22,24-27</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If serum potassium concentration is ≥5.5 mEq/L, we usually dialyze the patient before surgery, particularly if any hyperkalemia-induced changes in the ECG are evident  (<a class="graphic graphic_figure graphicRef109443" href="/d/graphic/109443.html" rel="external">figure 1</a>). Two to three hours of hemodialysis will typically suffice to prepare a patient for surgery. If the patient is on peritoneal dialysis, rapid exchanges can be performed to decrease the serum potassium if time permits, or the patient can receive urgent hemodialysis via a hemodialysis catheter. Gastrointestinal cation exchangers (eg, <a class="drug drug_general" data-topicid="104961" href="/d/drug information/104961.html" rel="external">patiromer</a> or <a class="drug drug_general" data-topicid="117928" href="/d/drug information/117928.html" rel="external">sodium zirconium cyclosilicate</a>) can also be used if the patient is not nil per os, but they are slower acting and unlikely to be effective if given shortly before surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Emergency surgery </strong>– For emergency surgical procedures, the nephrology service should be consulted when feasible to determine whether urgent preoperative dialysis may be appropriate to treat severe hyperkalemia. Institution of alternative therapies may be necessary if dialysis is not feasible. Emergency management of hyperkalemia during surgery is discussed separately. (See  <a class="medical medical_review" href="/d/html/94254.html" rel="external">"Anesthesia for dialysis patients", section on 'Emergency surgery considerations'</a>.)</p><p></p><p class="headingAnchor" id="H2453819310"><span class="h4">Volume overload</span><span class="headingEndMark"> — </span>Optimal volume status prior to surgery is based in part upon estimates of anticipated fluid to be administered and/or lost during surgery. As a result, a discussion with the surgeon and anesthesiologist regarding perioperative volume status goals is desirable:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonurgent surgery –</strong> Intravascular volume overload, in particular clinically significant pulmonary edema, is usually an indication for urgent preoperative dialysis. Typically, the goal of preoperative dialysis is to reach the patient's estimated dry weight. Additional factors are considered, such as the amount of volume that will be administered or anticipated blood loss during surgery. A patient who remains in pulmonary edema once their dry weight has been attained should be evaluated for a cardiac cause. (See <a class="local">'Routine dialysis prior to surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urgent or emergency surgery –</strong> For urgent or emergency surgery, the risks of mild, moderate, or severe circulatory volume increases are weighed against the risks of delaying surgery. Discussions among the surgeon, anesthesiologist, and nephrologist can avoid the following perioperative scenarios: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypervolemia and pulmonary edema in the immediate postoperative period necessitating dialysis and possibly noninvasive positive pressure ventilation or controlled mechanical ventilation. This may occur if euvolemia or estimated dry weight is not achieved in the preoperative period and/or the patient receives a large volume of fluid during surgery.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intraoperative hypotension due to anesthesia-induced systemic vasodilatation in a relatively hypovolemic patient, which may result in significant complications such as thrombosis of the arteriovenous access site. This may occur if too much fluid is removed during preoperative dialysis.</p><p></p><p class="headingAnchor" id="H1721477685"><span class="h3">Use of heparin</span><span class="headingEndMark"> — </span>If dialysis is performed on the day of surgery, we try to minimize or avoid use of heparin during dialysis. Heparin doses can be reduced and often eliminated by using <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> flushes during the hemodialysis treatment. If heparin is administered, we wait for the coagulation parameters to normalize prior to beginning surgery if feasible (typically within <strong>four hours</strong> of heparin termination).</p><p class="headingAnchor" id="H2732562888"><span class="h2">Medication management</span><span class="headingEndMark"> — </span>Perioperative medication management is similar to that for patients without ESKD, as discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4814.html" rel="external">"Perioperative medication management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) </strong>– In patients on dialysis who are taking ACE inhibitors or ARBs, we individualize the decision to continue or discontinue these agents based upon the indications for the drug, the patient's blood pressure, and the type of surgery and anesthesia planned. Many anesthesiologists may prefer to withhold these medications on the morning of surgery based on concerns about possible hypotension. However, when the indication is for heart failure or poorly controlled hypertension, we continue them to avoid further exacerbation of these conditions and inform the anesthesiologist of our rationale. If ACE inhibitors or ARBs are held, they are typically resumed on the first postoperative day if the patient is stable. (See  <a class="medical medical_review" href="/d/html/4814.html" rel="external">"Perioperative medication management", section on 'ACE inhibitors and angiotensin II receptor blockers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diuretics </strong>– In patients on dialysis who are taking chronically administered diuretics, the decision to continue or temporarily hold these agents is influenced by the patient's volume status prior to surgery. Diuretics can generally be continued if the patient is euvolemic or volume overloaded. If the patient appears volume depleted, we discontinue diuretics prior to surgery and restart them on the first postoperative day, if indicated and the patient is stable. (See  <a class="medical medical_review" href="/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Diuretics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta-blockers </strong>– We continue chronically administered beta blockers to prevent withdrawal. Beta blockers are typically resumed on the first postoperative day in stable patients. However, we do not initiate beta blockers prior to surgery in those who are not on beta blockers. (See  <a class="medical medical_review" href="/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Beta blockers'</a> and  <a class="medical medical_review" href="/d/html/6615.html" rel="external">"Management of cardiac risk for noncardiac surgery", section on 'Patients without indications for long-term therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9285" href="/d/drug information/9285.html" rel="external">Clonidine</a><strong> </strong>– We continue chronically administered clonidine to prevent withdrawal. However, we do not initiate alpha 2 agonist drugs in the perioperative period. (See  <a class="medical medical_review" href="/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Alpha 2 agonists'</a>.)</p><p></p><p class="headingAnchor" id="H303742183"><span class="h2">Intravenous access</span><span class="headingEndMark"> — </span>Obtaining intravascular access for the intraoperative period is often difficult in patients on dialysis. The hemodialysis catheter should be avoided. Also, meticulous care of an existing fistula is essential. Peripherally inserted central catheter (PICC) lines and midline catheters should be avoided. Details regarding intraoperative intravascular access are discussed separately. (See  <a class="medical medical_review" href="/d/html/94254.html" rel="external">"Anesthesia for dialysis patients", section on 'Intravenous access'</a>.)</p><p>During the preoperative period, displaying a sign at the patient's bedside or use of a special wrist band to save the designated arm for proposed or existing accesses (avoiding needle sticks or blood pressure measurements in the arm) is important. Patients need to be taught to remind health care professionals not to use the designated arm and to preserve the superficial veins of the designated arm for future arteriovenous fistulas. (See  <a class="medical medical_review" href="/d/html/1913.html" rel="external">"Central vein obstruction associated with upper extremity hemodialysis access"</a>.)</p><p class="headingAnchor" id="H3860594095"><span class="h2">Uremic bleeding</span><span class="headingEndMark"> — </span>Unacceptable uremic bleeding may occur in some patients (eg, those with a history of excessive bleeding from the hemodialysis access site or those who are not optimally dialyzed at the time of surgery) (see <a class="local">'Bleeding diathesis'</a> above). Preventive measures that can be implemented in the preoperative period to minimize or avoid clinically significant bleeding during and after surgery include:</p><p class="bulletIndent1"><span class="glyph">●</span>Raising the hematocrit to an appropriate level by transfusing red blood cells, based on individual patient-specific and procedure-specific factors. (See  <a class="medical medical_review" href="/d/html/1947.html" rel="external">"Uremic platelet dysfunction", section on 'Invasive procedures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Desmopressin – <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">Desmopressin</a> may be administered intravenous (IV) at a dose of 0.3 mcg/kg (in 50 mL of <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> over 15 to 30 minutes) or subcutaneously at a dose of 0.3 mcg/kg [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/1947.html" rel="external">"Uremic platelet dysfunction", section on 'Other measures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dialysis before surgery. (See <a class="local">'Dialysis considerations'</a> above.)</p><p></p><p>Management of bleeding in patients on dialysis during elective or emergency surgery is discussed in a separate topic. (See  <a class="medical medical_review" href="/d/html/94254.html" rel="external">"Anesthesia for dialysis patients", section on 'Management of bleeding'</a>.)</p><p class="headingAnchor" id="H3643755820"><span class="h2">Issues specific to peritoneal dialysis</span><span class="headingEndMark"> — </span>Several preoperative issues are unique to patients on peritoneal dialysis, including the use of antibiotics to prevent peritonitis and preoperative bowel preparation to minimize the effect of postoperative ileus on the resumption of dialysis. These and other issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/139769.html" rel="external">"Issues in patients on peritoneal dialysis undergoing surgery", section on 'Preoperative management'</a>.)</p><p class="headingAnchor" id="H2824138781"><span class="h1">INTRAOPERATIVE MANAGEMENT</span><span class="headingEndMark"> — </span>The intraoperative management of patients on dialysis, including anesthetic management, is discussed separately. (See  <a class="medical medical_review" href="/d/html/94254.html" rel="external">"Anesthesia for dialysis patients", section on 'Intraoperative anesthetic management'</a> and  <a class="medical medical_review" href="/d/html/139769.html" rel="external">"Issues in patients on peritoneal dialysis undergoing surgery", section on 'Intraoperative management'</a>.)</p><p class="headingAnchor" id="H2112849844"><span class="h1">POSTOPERATIVE MANAGEMENT</span></p><p class="headingAnchor" id="H3823525765"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Postoperative monitoring should include an assessment of volume status and hemodynamic stability. Laboratory testing is guided by the specific surgery as well as the results of preoperative lab testing. Patients should be closely monitored for the development of hyperkalemia.</p><p class="headingAnchor" id="H4239258504"><span class="h2">Resuming dialysis</span><span class="headingEndMark"> — </span>In the absence of an acute indication (such as hyperkalemia), dialysis may be resumed according to schedule. However, some patients may require more urgent dialysis to reduce their circulating volume immediately to facilitate weaning from a ventilator and extubation. Patients who undergo general anesthesia typically experience venodilation and arterial vasodilation. The infusion of volume to attain adequate filling pressures and venous return greatly aids in attaining hemodynamic stability, especially during major procedures. Patients appropriately resuscitated in this manner will have an excessive circulating volume after their anesthetic has worn off. If a patient has clinical symptoms, such as pulmonary edema or difficult to control hypertension, it is reasonable to arrange expeditious hemodialysis and ultrafiltration. </p><p>Changes to the peritoneal dialysis prescription after abdominal and cardiothoracic surgery, as well as postoperative indications to switch from peritoneal dialysis to another mode of kidney replacement therapy, are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/139769.html" rel="external">"Issues in patients on peritoneal dialysis undergoing surgery", section on 'Postoperative management'</a>.)</p><p>After major surgery, heparin with hemodialysis should be avoided for the first 24 to 48 postoperative hours, particularly if the site of surgery is not easy to assess for evidence of postoperative bleeding, or if any bleeding would result in catastrophic consequences (eg, intracranial or intraocular bleeding). Alternatives to the administration of heparin are readily available, including no-heparin hemodialysis. Alternatively, if there is no specific indication for dialysis, we may delay a treatment for 24 to 48 hours postoperatively. Discussion with the surgeon concerning these issues is vital. (See  <a class="medical medical_review" href="/d/html/1840.html" rel="external">"Anticoagulation for the hemodialysis procedure"</a>.)</p><p>Patients should be followed closely for subsequent dialysis needs. Capillary leak and fluid accumulation often start to occur at 48 to 72 hours postoperatively, causing pulmonary edema and demand ischemia.</p><p class="headingAnchor" id="H934935304"><span class="h2">Pain management</span><span class="headingEndMark"> — </span>A multimodal approach to postoperative analgesia is used when feasible. (See  <a class="medical medical_review" href="/d/html/130312.html" rel="external">"Approach to the management of acute pain in adults", section on 'Use multimodal analgesia'</a> and  <a class="medical medical_review" href="/d/html/94254.html" rel="external">"Anesthesia for dialysis patients", section on 'Postoperative analgesia'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic agents – </strong>Pain relief may be provided by a variety of agents, including opioids and <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>. Some opioids should not be used in patients with end-stage kidney disease (ESKD), and caution must be used in dosing any opioid. This is particularly important in patients on hemodialysis who are at high risk for opioid-related side effects and drug-drug interactions [<a href="#rid28">28,29</a>]. Furthermore, acute alkalinization with hemodialysis may increase distribution of opioids across the blood-brain barrier into cerebrospinal fluid. (See  <a class="medical medical_review" href="/d/html/93774.html" rel="external">"Management of chronic pain in advanced chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Opioid use</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">Fentanyl</a> is the opioid of choice for postoperative use patients on dialysis (eg, for patient-controlled analgesia) [<a href="#rid30">30</a>]. Fentanyl is well tolerated because of its short redistribution phase, lack of active metabolites, and unchanged free fraction [<a href="#rid31">31</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hydromorphone is also commonly used in the postoperative period in patients with ESKD.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Opioids to avoid</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">Meperidine</a> (Demerol, pethidine) is avoided. Meperidine is metabolized in the liver to an active metabolite normeperidine, which has an extremely long half-life in patients on dialysis [<a href="#rid32">32</a>]. Since normeperidine is excreted both by the liver and kidneys, failure of either organ causes elevated levels. In addition, adverse side effects of normeperidine include myoclonic jerks, seizures, as well as respiratory depression [<a href="#rid33">33-35</a>]. The central nervous system excitatory effects are directly related to elevated normeperidine-to-meperidine ratios [<a href="#rid36">36</a>]. Notably, these adverse excitatory effects are not reversed but may actually be enhanced by <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a>.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">Morphine</a> is generally avoided or used cautiously in patients with ESKD since its sedative effects are also prolonged [<a href="#rid37">37</a>]. Morphine is metabolized by hepatic glucuronidase to morphine 3 glucuronide (M3G) and morphine 6 glucuronide (M6G) [<a href="#rid38">38</a>]. In patients with kidney failure, the half-life is unchanged for morphine, but it is prolonged for both M3G and M6G; these last two agents are both pharmacologically active, thereby explaining the prolonged effect of the drug in kidney failure [<a href="#rid39">39</a>]. Morphine and M6G are both removed by hemodialysis [<a href="#rid40">40-42</a>]; however, M6G diffuses out of the central nervous system slowly, which may delay the response to dialysis [<a href="#rid42">42</a>]. Data on the dialyzability of M3G are not available. Peritoneal dialysis does not enhance the clearance of the metabolites of morphine [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonopioid analgesic agents</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Acetaminophen</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">Acetaminophen</a> can be used in patients on dialysis without dose modification [<a href="#rid32">32,44</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Ketamine</strong><strong> </strong>–<strong> </strong>Use of <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> has been described for very painful surgical procedures [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Gabapentinoids </strong>–<strong> </strong>Although gabapentinoids are used in some institutions as a component of multimodal pain management, patients with ESKD are particularly vulnerable to adverse side effects such as excessive sedation and respiratory depression [<a href="#rid44">44,45</a>]. If a gabapentinoid is used, the dose should be decreased.<strong> </strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local anesthetic techniques </strong>–<strong> </strong>The anesthesiologist may employ regional analgesia (neuraxial or peripheral nerve block) or the surgeon may employ wound infiltration to reduce or eliminate opioid dosing in the postoperative period. (See  <a class="medical medical_review" href="/d/html/94254.html" rel="external">"Anesthesia for dialysis patients", section on 'Postoperative analgesia'</a>.)</p><p></p><p class="headingAnchor" id="H832023620"><span class="h2">Anemia management</span><span class="headingEndMark"> — </span>Despite being at target hemoglobin, patients may require transfusions postoperatively due to substantial intra- or postoperative blood loss. In patients awaiting kidney transplant, it is important to limit the number of blood transfusions, if possible, to minimize the risk of sensitization. (See  <a class="medical medical_review" href="/d/html/7302.html" rel="external">"Kidney transplantation in adults: Risk factors for graft failure", section on 'Human leukocyte antigen matching'</a>.)</p><p>In addition, patients are often resistant to erythropoiesis-stimulating agents (ESAs) in the postoperative period, possibly due to increased inflammation and elevated hepcidin levels [<a href="#rid46">46</a>]. We continue the ESA throughout hospitalization despite the possibility that the patient may be relatively less responsive. If the patient is hyporesponsive to the ESA and their iron stores are adequate, increasing the dose of the ESA may be reasonable. Alternatively, if the patient is only moderately anemic, the prior dose can simply be maintained.  </p><p class="headingAnchor" id="H1258030171"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H2593737146"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperative evaluation </strong>– For most planned surgical procedures, preoperative medical evaluation of patients on dialysis includes baseline laboratory testing, determining the adequacy of hemodialysis or peritoneal dialysis access, and assessing for comorbidities, including cardiovascular disease, hypertension, diabetes, anemia, bleeding diathesis, and nutritional status. (See <a class="local">'Preoperative evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperative management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Routine dialysis prior to surgery </strong>– For those patients undergoing elective surgery who are on maintenance hemodialysis, a hemodialysis treatment is usually performed when practical, either the day before or on the day of the procedure. For well-dialyzed patients who are on peritoneal dialysis, some but not all experts increase the amount of dialysis before elective surgery. (See <a class="local">'Routine dialysis prior to surgery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications for urgent preoperative dialysis </strong>– The major indications for urgent preoperative dialysis are hyperkalemia and volume overload.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with a serum potassium ≥5.5 mEq/L generally require preoperative dialysis, particularly if electrocardiographic (ECG) features of hyperkalemia  (<a class="graphic graphic_figure graphicRef109443" href="/d/graphic/109443.html" rel="external">figure 1</a>) are present. However, if dialysis cannot be performed prior to surgery, we treat with medical management. For patients with a serum potassium &lt;5.5 mEq/L and no ECG changes, urgent dialysis is not necessary prior to surgery. In a true emergency, life-threatening surgical situation, the operation is performed regardless of potassium level. (See <a class="local">'Hyperkalemia'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients should be at or close to dry weight prior to surgery. The optimal volume status prior to surgery depends on estimations of the amount of fluid to be administered and/or lost during surgery. A discussion with the surgeon and anesthesiologist regarding perioperative volume status goals is desirable. (See <a class="local">'Volume overload'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medication management </strong>– Perioperative medication management is similar to that for patients without end-stage kidney disease (ESKD). (See <a class="local">'Medication management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intravenous (IV) access –</strong> Obtaining IV access for the intraoperative period is often difficult in patients on dialysis. The hemodialysis catheter is avoided. Also, meticulous care of an existing fistula is essential. Peripherally inserted central catheter (PICC) lines should be avoided. (See <a class="local">'Intravenous access'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Uremic bleeding </strong>– Uremic bleeding may occur in some patients. Preventive measures that can be implemented in the preoperative period to minimize or avoid clinically significant bleeding during and after surgery include red blood cell transfusion, <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>, and dialysis before surgery. (See <a class="local">'Uremic bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative management </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Resuming dialysis </strong>– In the absence of an acute indication (such as hyperkalemia or volume overload), dialysis is usually resumed according to schedule. However, some patients may require more urgent dialysis to treat volume overload immediately after surgery in order to facilitate weaning from a ventilator and extubation. After some surgeries, patients on peritoneal dialysis may require modification to their dialysis prescription, or, less commonly, may need to switch temporarily from peritoneal dialysis to another mode of kidney replacement therapy. (See <a class="local">'Resuming dialysis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pain management </strong>– A multimodal approach to postoperative analgesia is used when feasible. Pain relief may be provided by a variety of agents, including opioids and <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>. <a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">Meperidine</a>, propoxyphene, and <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> should generally be avoided. (See <a class="local">'Pain management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anemia management –</strong> Although erythropoiesis-stimulating agents (ESAs) are typically administered preoperatively in patients whose hemoglobin levels are less than the target before surgery, patients may require postoperative transfusions if intra- or postoperative blood loss is substantial. In patients awaiting kidney transplant, it is important to limit the number of blood transfusions, if possible, to minimize the risk of sensitization. Patients may be resistant to ESAs in the postoperative period, but we continue this treatment throughout hospitalization. (See <a class="local">'Anemia management'</a> above.)</p><p></p><p class="headingAnchor" id="H1339577866"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Liza M Weavind, MBBCh, FCCM, MMHC, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kellerman PS. Perioperative care of the renal patient. Arch Intern Med 1994; 154:1674.</a></li><li><a class="nounderline abstract_t">Hansen LS, Hjortdal VE, Andreasen JJ, et al. 30-day mortality after coronary artery bypass grafting and valve surgery has greatly improved over the last decade, but the 1-year mortality remains constant. Ann Card Anaesth 2015; 18:138.</a></li><li><a class="nounderline abstract_t">Yuo TH, Sidaoui J, Marone LK, et al. Limited survival in dialysis patients undergoing intact abdominal aortic aneurysm repair. J Vasc Surg 2014; 60:908.</a></li><li><a class="nounderline abstract_t">Elkouri S, Gloviczki P, McKusick MA, et al. Perioperative complications and early outcome after endovascular and open surgical repair of abdominal aortic aneurysms. J Vasc Surg 2004; 39:497.</a></li><li><a class="nounderline abstract_t">Schermerhorn ML, O'Malley AJ, Jhaveri A, et al. Endovascular vs. open repair of abdominal aortic aneurysms in the Medicare population. N Engl J Med 2008; 358:464.</a></li><li><a class="nounderline abstract_t">Anderson PL, Arons RR, Moskowitz AJ, et al. A statewide experience with endovascular abdominal aortic aneurysm repair: rapid diffusion with excellent early results. J Vasc Surg 2004; 39:10.</a></li><li><a class="nounderline abstract_t">Pinson CW, Schuman ES, Gross GF, et al. Surgery in long-term dialysis patients. Experience with more than 300 cases. Am J Surg 1986; 151:567.</a></li><li><a class="nounderline abstract_t">Deutsch E, Bernstein RC, Addonizio P, Kussmaul WG 3rd. Coronary artery bypass surgery in patients on chronic hemodialysis. A case-control study. Ann Intern Med 1989; 110:369.</a></li><li><a class="nounderline abstract_t">Steiner RW, Coggins C, Carvalho AC. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol 1979; 7:107.</a></li><li><a class="nounderline abstract_t">Liu YK, Goldstein DM, Arora K, et al. Thigh bleeding time as a valid indicator of hemostatic competency during surgical treatment of patients with advanced renal disease. Surg Gynecol Obstet 1991; 172:269.</a></li><li><a class="nounderline abstract_t">Brown JH, Hunt LP, Vites NP, et al. Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 1994; 9:1136.</a></li><li><a class="nounderline abstract_t">Schreiber S, Korzets A, Powsner E, Wolloch Y. Surgery in chronic dialysis patients. Isr J Med Sci 1995; 31:479.</a></li><li><a class="nounderline abstract_t">Ahmad Y, Bellamy MF, Baker CSR. Aortic Stenosis in Dialysis Patients. Semin Dial 2017; 30:224.</a></li><li><a class="nounderline abstract_t">Shroff GR, Bangalore S, Bhave NM, et al. Evaluation and Management of Aortic Stenosis in Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Circulation 2021; 143:e1088.</a></li><li><a class="nounderline abstract_t">Jalal DI, Chonchol M, Targher G. Disorders of hemostasis associated with chronic kidney disease. Semin Thromb Hemost 2010; 36:34.</a></li><li><a class="nounderline abstract_t">Remuzzi G. Bleeding in renal failure. Lancet 1988; 1:1205.</a></li><li><a class="nounderline abstract_t">Pivalizza EG, Abramson DC, Harvey A. Perioperative hypercoagulability in uremic patients: a viscoelastic study. J Clin Anesth 1997; 9:442.</a></li><li><a class="nounderline abstract_t">Pawlak K, Mysliwiec M, Pawlak D. Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients. Thromb Haemost 2009; 102:49.</a></li><li><a class="nounderline abstract_t">Bonomini M, Sirolli V, Merciaro G, et al. Red blood cells may contribute to hypercoagulability in uraemia via enhanced surface exposure of phosphatidylserine. Nephrol Dial Transplant 2005; 20:361.</a></li><li><a class="nounderline abstract_t">de Mutsert R, Grootendorst DC, Axelsson J, et al. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant 2008; 23:2957.</a></li><li><a class="nounderline abstract_t">Fielding-Singh V, Vanneman MW, Grogan T, et al. Association Between Preoperative Hemodialysis Timing and Postoperative Mortality in Patients With End-stage Kidney Disease. JAMA 2022; 328:1837.</a></li><li><a class="nounderline abstract_t">Aslam S, Friedman EA, Ifudu O. Electrocardiography is unreliable in detecting potentially lethal hyperkalaemia in haemodialysis patients. Nephrol Dial Transplant 2002; 17:1639.</a></li><li><a class="nounderline abstract_t">Plane AF, Marsan PE, du Cheyron D, Valette X. Rapidly changing ECG in hyperkalaemia after succinylcholine. Lancet 2019; 393:1983.</a></li><li><a class="nounderline abstract_t">Khattak HK, Khalid S, Manzoor K, Stein PK. Recurrent life-threatening hyperkalemia without typical electrocardiographic changes. J Electrocardiol 2014; 47:95.</a></li><li><a class="nounderline abstract_t">Cobo Sánchez JL, Alconero Camarero AR, Casaus Pérez M, et al. Hyperkalaemia and haemodialysis patients: eletrocardiographic changes. J Ren Care 2007; 33:124.</a></li><li><a class="nounderline abstract_t">Ahmed J, Weisberg LS. Hyperkalemia in dialysis patients. Semin Dial 2001; 14:348.</a></li><li><a class="nounderline abstract_t">Esposito C, Bellotti N, Fasoli G, et al. Hyperkalemia-induced ECG abnormalities in patients with reduced renal function. Clin Nephrol 2004; 62:465.</a></li><li><a class="nounderline abstract_t">Ishida JH, McCulloch CE, Steinman MA, et al. Opioid Analgesics and Adverse Outcomes among Hemodialysis Patients. Clin J Am Soc Nephrol 2018; 13:746.</a></li><li><a class="nounderline abstract_t">Tawfic QA, Bellingham G. Postoperative pain management in patients with chronic kidney disease. J Anaesthesiol Clin Pharmacol 2015; 31:6.</a></li><li><a class="nounderline abstract_t">Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004; 28:497.</a></li><li><a class="nounderline abstract_t">Sear JW. Kidney transplants: induction and analgesic agents. Int Anesthesiol Clin 1995; 33:45.</a></li><li><a class="nounderline abstract_t">Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis 2003; 42:217.</a></li><li><a class="nounderline abstract_t">Geller RJ. Meperidine in patient-controlled analgesia: a near-fatal mishap. Anesth Analg 1993; 76:655.</a></li><li class="breakAll">Gillman AG, Rall TW, Nies AS, et al. Goodman and Gillman's the Pharmacologic Basis of Therapeutics, 8th ed., Pergamon Press, New York 1990. p.504.</li><li><a class="nounderline abstract_t">Szeto HH, Inturrisi CE, Houde R, et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. Ann Intern Med 1977; 86:738.</a></li><li><a class="nounderline abstract_t">Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983; 13:180.</a></li><li class="breakAll">Bansal VK, Vertuno LL. Handbook of Dialysis, 2nd ed., Daugirdas JR, Ing TS (Eds), Little Brown and Co, 1994  p.551.</li><li><a class="nounderline abstract_t">Peterson GM, Randall CT, Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol 1990; 38:121.</a></li><li><a class="nounderline abstract_t">Chauvin M, Sandouk P, Scherrmann JM, et al. Morphine pharmacokinetics in renal failure. Anesthesiology 1987; 66:327.</a></li><li><a class="nounderline abstract_t">Bion JF, Logan BK, Newman PM, et al. Sedation in intensive care: morphine and renal function. Intensive Care Med 1986; 12:359.</a></li><li><a class="nounderline abstract_t">Bastani B, Jamal JA. Removal of morphine but not fentanyl during haemodialysis. Nephrol Dial Transplant 1997; 12:2802.</a></li><li><a class="nounderline abstract_t">Angst MS, Bührer M, Lötsch J. Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action. Anesthesiology 2000; 92:1473.</a></li><li><a class="nounderline abstract_t">Hanna MH, D'Costa F, Peat SJ, et al. Morphine-6-glucuronide disposition in renal impairment. Br J Anaesth 1993; 70:511.</a></li><li><a class="nounderline abstract_t">Ohnuma T, Horres CR 3rd, Raghunathan K, et al. Trends in multimodal analgesics among end-stage renal disease patients undergoing lower extremity amputation in the US from 2009 to 2018. Br J Anaesth 2022; 128:e43.</a></li><li><a class="nounderline abstract_t">Ishida JH, McCulloch CE, Steinman MA, et al. Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients. J Am Soc Nephrol 2018; 29:1970.</a></li><li><a class="nounderline abstract_t">Hung M, Ortmann E, Besser M, et al. A prospective observational cohort study to identify the causes of anaemia and association with outcome in cardiac surgical patients. Heart 2015; 101:107.</a></li></ol></div><div id="topicVersionRevision">Topic 1899 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8042884" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Perioperative care of the renal patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25849679" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 30-day mortality after coronary artery bypass grafting and valve surgery has greatly improved over the last decade, but the 1-year mortality remains constant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24854417" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Limited survival in dialysis patients undergoing intact abdominal aortic aneurysm repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981437" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Perioperative complications and early outcome after endovascular and open surgical repair of abdominal aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18234751" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Endovascular vs. open repair of abdominal aortic aneurysms in the Medicare population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14718804" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A statewide experience with endovascular abdominal aortic aneurysm repair: rapid diffusion with excellent early results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3706632" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Surgery in long-term dialysis patients. Experience with more than 300 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2783839" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Coronary artery bypass surgery in patients on chronic hemodialysis. A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/539588" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bleeding time in uremia: a useful test to assess clinical bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2006450" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Thigh bleeding time as a valid indicator of hemostatic competency during surgical treatment of patients with advanced renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7800214" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Comparative mortality from cardiovascular disease in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7635697" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Surgery in chronic dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28239994" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Aortic Stenosis in Dialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33980041" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Evaluation and Management of Aortic Stenosis in Chronic Kidney Disease: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20391294" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Disorders of hemostasis associated with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2897015" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bleeding in renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9278828" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Perioperative hypercoagulability in uremic patients: a viscoelastic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19572067" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15598665" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Red blood cells may contribute to hypercoagulability in uraemia via enhanced surface exposure of phosphatidylserine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18400817" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36326747" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Association Between Preoperative Hemodialysis Timing and Postoperative Mortality in Patients With End-stage Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12198216" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Electrocardiography is unreliable in detecting potentially lethal hyperkalaemia in haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31084970" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Rapidly changing ECG in hyperkalaemia after succinylcholine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23973093" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Recurrent life-threatening hyperkalemia without typical electrocardiographic changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19160884" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hyperkalaemia and haemodialysis patients: eletrocardiographic changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11679104" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hyperkalemia in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15630907" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hyperkalemia-induced ECG abnormalities in patients with reduced renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29674340" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Opioid Analgesics and Adverse Outcomes among Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25788766" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Postoperative pain management in patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15504625" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Opioids in renal failure and dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7657380" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Kidney transplants: induction and analgesic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12900801" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Analgesia in patients with ESRD: a review of available evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8452285" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Meperidine in patient-controlled analgesia: a near-fatal mishap.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8452285" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Meperidine in patient-controlled analgesia: a near-fatal mishap.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/869353" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6187275" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Central nervous system excitatory effects of meperidine in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6187275" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Central nervous system excitatory effects of meperidine in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2338107" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3826690" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Morphine pharmacokinetics in renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3771914" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Sedation in intensive care: morphine and renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9430910" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Removal of morphine but not fentanyl during haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10781294" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8318321" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Morphine-6-glucuronide disposition in renal impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34852927" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Trends in multimodal analgesics among end-stage renal disease patients undergoing lower extremity amputation in the US from 2009 to 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29871945" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25217489" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A prospective observational cohort study to identify the causes of anaemia and association with outcome in cardiac surgical patients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
